LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday

Key Points

• LENZ Therapeutics is set to announce its Q2 2025 earnings on August 13th, expecting to report a loss of ($0.62) per share.
• The stock has shown notable growth, with a market capitalization of $869.29 million and recent trading up by 3.9%.
• LENZ has garnered a consensus rating of "Buy" from five research analysts, with target prices ranging from $40.00 to $51.00.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.05. The company had revenue of $5.00 million for the quarter, compared to analyst estimates of $5.00 million. On average, analysts expect LENZ Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Trading Up 8.0%

NASDAQ LENZ traded up $2.56 on Friday, hitting $34.68. 1,136,207 shares of the company were exchanged, compared to its average volume of 384,565. The firm has a 50 day moving average of $31.26 and a two-hundred day moving average of $27.24. The company has a market cap of $989.07 million, a P/E ratio of -18.25 and a beta of 0.42. LENZ Therapeutics has a 1-year low of $16.53 and a 1-year high of $38.93.

Hedge Funds Weigh In On LENZ Therapeutics

A hedge fund recently bought a new stake in LENZ Therapeutics stock. Creative Planning acquired a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 14,068 shares of the company's stock, valued at approximately $412,000. Hedge funds and other institutional investors own 54.32% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on LENZ shares. Piper Sandler started coverage on LENZ Therapeutics in a report on Monday, April 14th. They set an "overweight" rating and a $51.00 price objective for the company. Citigroup reissued a "buy" rating and set a $49.00 price objective (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday, July 31st. Raymond James Financial boosted their price objective on LENZ Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, July 31st. Finally, HC Wainwright upped their price target on LENZ Therapeutics from $38.00 to $48.00 and gave the company a "buy" rating in a research note on Monday, July 28th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $49.60.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.